Health Care Fund
Daily price w/o sales charge as of 06/09/2023
$18.35
$0.04
YTD Returns w/o sales charge as of 06/09/2023
5.46%
Overall Morningstar RatingsHealth
as of 05/31/2023
Morningstar rated the Lord Abbett Health Care Fund class A share 4 stars among 152 Health Funds for the overall rating and the 3 year periods ended 5/31/2023, respectively.
Please click here for performance current to the most recent quarter-end and month-end.
Summary
Summary
The Fund seeks to deliver long-term growth of capital by investing primarily in stocks of companies within the health care sector.
Fund Basicsas of 04/28/2023
- Total Net Assets
- $7.89 M
- Inception Date
- 08/01/2019
- Dividend Frequency
- Monthly (Daily Accrual)
- Fund Gross Expense Ratio
- 4.11%
- Fund Net Expense Ratio
- 1.03%
- Number of Holdings
- 73
- Minimum Initial Investment
- $1,500+
Fund Expense Ratio :
Gross 4.11%
Net 1.03%
YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
---|
w/o sales charge | 2.47% | 7.34% | 7.64% | - | - | 10.05% |
Lipper Category Avg. Health/Biotechnology Funds | -0.66% | 6.35% | 3.18% | - | - | - |
MSCI ACWI Health Care Index (Net) | -2.46% | -0.45% | 6.27% | - | - | 9.20% |
w/ sales charge | -3.41% | 1.19% | 5.53% | - | - | 8.36% |
Fund Expense Ratio :
Gross 4.11%
Net 1.03%
Fund Expense Ratio :
Gross 4.11%
Net 1.03%
YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
---|
w/o sales charge | -1.26% | -5.86% | 13.30% | - | - | 9.42% |
Lipper Category Avg. Health/Biotechnology Funds | -1.41% | -6.96% | 10.04% | - | - | - |
MSCI ACWI Health Care Index (Net) | -1.72% | -4.12% | 12.01% | - | - | 9.87% |
w/ sales charge | -6.93% | -11.26% | 11.08% | - | - | 7.66% |
Fund Expense Ratio :
Gross 4.11%
Net 1.03%
The performance quoted represents past performance, which is no indication of future results. Current performance may be higher or lower than the performance data quoted. Returns shown include the reinvestment of all distributions. Returns shown at net asset value do not reflect the current maximum sales charge, had the sales charge been included, returns would have been lower. The investment return and principal value of an investment will fluctuate so that shares, on any given day or when redeemed, may be worth more or less than the original cost. Therefore, there can be no assurance for future results.
Returns with sales charge reflect a maximum sales charge of 5.75%
INVESTMENT TEAM




Contact a Representative
To contact your representative, enter your zip code and select your channel below.
Performance
Performance
Fund Expense Ratio :
Gross 4.11%
Net 1.03%
YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
---|
w/o sales charge | 2.47% | 7.34% | 7.64% | - | - | 10.05% |
Lipper Category Avg. Health/Biotechnology Funds | -0.66% | 6.35% | 3.18% | - | - | - |
MSCI ACWI Health Care Index (Net) | -2.46% | -0.45% | 6.27% | - | - | 9.20% |
w/ sales charge | -3.41% | 1.19% | 5.53% | - | - | 8.36% |
Fund Expense Ratio :
Gross 4.11%
Net 1.03%
Fund Expense Ratio :
Gross 4.11%
Net 1.03%
YTD | 1-YR | 3-YR | 5-YR | 10-YR | Since Inception 07/31/2019 |
---|
w/o sales charge | -1.26% | -5.86% | 13.30% | - | - | 9.42% |
Lipper Category Avg. Health/Biotechnology Funds | -1.41% | -6.96% | 10.04% | - | - | - |
MSCI ACWI Health Care Index (Net) | -1.72% | -4.12% | 12.01% | - | - | 9.87% |
w/ sales charge | -6.93% | -11.26% | 11.08% | - | - | 7.66% |
Fund Expense Ratio :
Gross 4.11%
Net 1.03%
The performance quoted represents past performance, which is no indication of future results. Current performance may be higher or lower than the performance data quoted. Returns shown include the reinvestment of all distributions. Returns shown at net asset value do not reflect the current maximum sales charge, had the sales charge been included, returns would have been lower. The investment return and principal value of an investment will fluctuate so that shares, on any given day or when redeemed, may be worth more or less than the original cost. Therefore, there can be no assurance for future results.
NAV Historical Prices
Date | Net Asset Value |
---|
Portfolio
Portfolio
Portfolio Details as of 04/28/2023
- Total Net Assets
- $7.89 M
- Number of Holdings
- 73
- Weighted Average Market Cap.
- 97.1 B
- P/B Ratio
- 6.5x
- P/E Ratio
- 38.4x
To view definitions for the above Portfolio Details, Click here.
Holding | Sector | Assets |
---|
Eli Lilly & Co | Health Care | 5.3% |
UnitedHealth Group Inc | Health Care | 3.7% |
Novo Nordisk A/S | Health Care | 3.6% |
AstraZeneca PLC | Health Care | 3.5% |
MERCK + CO INC | Health Care | 3.5% |
Vertex Pharmaceuticals Inc | Health Care | 3.1% |
Intuitive Surgical Inc | Health Care | 2.4% |
Regeneron Pharmaceuticals Inc | Health Care | 2.3% |
Humana Inc | Health Care | 2.0% |
Stryker Corp | Health Care | 2.0% |
Aggregate holdings are updated monthly, 30 days after month end. Aggregate holdings are presented to illustrate examples of the securities that the Fund has bought and the diversity of the areas in which the Fund may invest, and may not be representative of the Fund's current or future investments. The figures presented are as of the date shown and may change at any time.
Holding | Sector | Assets |
---|
Eli Lilly & Co | Health Care | 5.3% |
UnitedHealth Group Inc | Health Care | 3.7% |
Novo Nordisk A/S | Health Care | 3.6% |
AstraZeneca PLC | Health Care | 3.5% |
MERCK + CO INC | Health Care | 3.5% |
Vertex Pharmaceuticals Inc | Health Care | 3.1% |
Intuitive Surgical Inc | Health Care | 2.4% |
Regeneron Pharmaceuticals Inc | Health Care | 2.3% |
Humana Inc | Health Care | 2.0% |
Stryker Corp | Health Care | 2.0% |
Dexcom Inc | Health Care | 1.9% |
Insulet Corp | Health Care | 1.9% |
IDEXX Laboratories Inc | Health Care | 1.9% |
Apellis Pharmaceuticals Inc | Health Care | 1.8% |
Ventyx Biosciences Inc | Health Care | 1.8% |
Xenon Pharmaceuticals Inc | Health Care | 1.8% |
Daiichi Sankyo Co Ltd | Health Care | 1.7% |
Argenx SE | Health Care | 1.6% |
Eisai Co Ltd | Health Care | 1.5% |
TransMedics Group Inc | Health Care | 1.5% |
Karuna Therapeutics Inc | Health Care | 1.5% |
Arcellx Inc | Health Care | 1.5% |
West Pharmaceutical Services Inc | Health Care | 1.5% |
Krystal Biotech Inc | Health Care | 1.4% |
Align Technology Inc | Health Care | 1.4% |
Danaher Corp | Health Care | 1.3% |
Inspire Medical Systems Inc | Health Care | 1.3% |
Natera Inc | Health Care | 1.3% |
10X Genomics Inc | Health Care | 1.3% |
Boston Scientific Corp | Health Care | 1.2% |
Straumann Holding AG | Health Care | 1.1% |
Mettler-Toledo International Inc | Health Care | 1.1% |
Lantheus Holdings Inc | Health Care | 1.1% |
Axonics Inc | Health Care | 1.1% |
Thermo Fisher Scientific Inc | Health Care | 1.1% |
Pliant Therapeutics Inc | Health Care | 1.1% |
Biogen Inc | Health Care | 1.1% |
Intra-Cellular Therapies Inc | Health Care | 1.1% |
Gerresheimer AG | Health Care | 1.1% |
Cooper Cos Inc/The | Health Care | 1.0% |
Cytokinetics Inc | Health Care | 1.0% |
Siemens Healthineers AG | Health Care | 1.0% |
Sarepta Therapeutics Inc | Health Care | 1.0% |
Shockwave Medical Inc | Health Care | 1.0% |
Penumbra Inc | Health Care | 1.0% |
Abbott Laboratories | Health Care | 0.9% |
Bachem Holding AG | Health Care | 0.9% |
Illumina Inc | Health Care | 0.9% |
Olink Holding AB | Health Care | 0.9% |
Neurocrine Biosciences Inc | Health Care | 0.8% |
iRhythm Technologies Inc | Health Care | 0.8% |
89bio Inc | Health Care | 0.8% |
BeiGene Ltd | Health Care | 0.8% |
Lonza Group AG | Health Care | 0.7% |
Legend Biotech Corp | Health Care | 0.7% |
Rocket Pharmaceuticals Inc | Health Care | 0.7% |
Laboratory Corp of America Holdings | Health Care | 0.7% |
Sartorius Stedim Biotech | Health Care | 0.7% |
Silk Road Medical Inc | Health Care | 0.7% |
Pacific Biosciences of California Inc | Health Care | 0.7% |
Molina Healthcare Inc | Health Care | 0.6% |
uniQure NV | Health Care | 0.6% |
Madrigal Pharmaceuticals Inc | Health Care | 0.6% |
Phreesia Inc | Health Care | 0.6% |
Glaukos Corp | Health Care | 0.6% |
Viking Therapeutics Inc | Health Care | 0.6% |
R1 RCM Inc | Health Care | 0.6% |
Cerevel Therapeutics Holdings Inc | Health Care | 0.6% |
Evolent Health Inc | Health Care | 0.5% |
Day One Biopharmaceuticals Inc | Health Care | 0.5% |
Genmab A/S | Health Care | 0.5% |
Repligen Corp | Health Care | 0.5% |
Cytek Biosciences Inc | Health Care | 0.4% |
Aggregate holdings are updated monthly, 30 days after month end. Aggregate holdings are presented to illustrate examples of the securities that the Fund has bought and the diversity of the areas in which the Fund may invest, and may not be representative of the Fund's current or future investments. The figures presented are as of the date shown and may change at any time.
Fees & Expenses
Fees & Expenses
Sales Charge Schedule as of 06/09/2023
Sales Charge | Dealer's Concession | Prices at Breakpoint | |
---|---|---|---|
Less than $50,000 | 5.75% | 5.00% | $19.47 |
$50,000 to $99,999 | 4.75% | 4.00% | $19.27 |
$100,000 to $249,999 | 3.95% | 3.25% | $19.10 |
$250,000 to $499,999 | 2.75% | 2.25% | $18.87 |
$500,000 to $999,999 | 1.95% | 1.75% | $18.71 |
$1,000,000 to $5,000,000 | 0.00% | 1.00% | $18.35 |
Class A shares purchased without a sales charge (commissionable NAV) will be subject to a CDSC of 1% if they are redeemed before the first day of the month in which the one-year anniversary of the purchase falls.
Expense Ratioas of 05/31/2023
Fund Gross Expense Ratio | Fund Net Expense Ratio | |
---|---|---|
4.11% | 1.03% |
Expense ratio details, Click here.
The net expense ratio takes into account contractual fee waivers/expense reimbursements that currently are scheduled to remain in place through 02/29/2024. For periods when fees and expenses were waived and/or reimbursed, the Fund benefited by not bearing such expenses. Without such fee waivers/reimbursements, performance would have been lower.
Fund Documents
Fund Documents
Download fund documents & literature, create email subscriptions, and place direct mail order
0Documents selected
|
Order | ||||
---|---|---|---|---|---|
n/a |
Portfolio Holdings 1Q
Publish Date:11/03/2015
|
||||
n/a |
Portfolio Holdings 3Q
Publish Date:11/03/2015
|
||||
Summary Prospectus
Publish Date:11/03/2015
|
|||||
n/a |
Statutory Prospectus
Publish Date:11/03/2015
|
||||
SAI
Publish Date:11/03/2015
|
|||||
Annual Report
Publish Date:11/03/2015
|
|||||
Semi-Annual Report
Publish Date:11/03/2015
|
|||||
Fact Sheet
Publish Date:11/03/2015
|